Exagen Inc. Q2 2026 Earnings Call Summary
Exagen Inc. reported record Q2 2026 revenue of $19.9 million, up 16% year over year, helped by record AVISE test volumes and higher trailing 12-month ASP near $446. The company raised full-year 2026 revenue guidance to $72 million to $75 million and expects adjusted EBITDA breakeven around $80 million of revenue. Exagen also discussed collections, reimbursement timing, and a myositis product launch in early 2027.
How this was made
The 30-second read
Why it matters
Traders can update expectations for FY2026 revenue and the timing of adjusted EBITDA breakeven based on the raised guidance and stated operating leverage, while monitoring reimbursement and seasonality assumptions that could drive second-half volatility.
Market read
A concrete FY2026 guidance raise plus a stated EBITDA breakeven revenue threshold provides a tradable catalyst, but second-half seasonality and reimbursement/LCD timing uncertainty can create downside risk.
What to watch
Collections from older claims and payer appeals are variable; the article highlights $1M+ from claims older than 360 days, which can make quarter-to-quarter comparability noisy.
Background
The piece summarizes Exagen’s Q2 2026 earnings call, focusing on revenue drivers, ASP growth, collections, and a commercialization roadmap for new stand-alone products.
Ticker impact
Exagen raised full-year 2026 revenue guidance to $72M-$75M and guided to sustainable adjusted EBITDA breakeven near $80M revenue.
Bias modestly positive into the next earnings/seasonality window, with volatility risk around second-half working-day and LCD timing assumptions.
The article discloses specific updated financial targets (revenue range, EBITDA breakeven level) plus operational drivers (ASP growth, collections, new product commercialization timing). It also flags uncertainty around MolDX LCD timing and second-half seasonality, which can temper follow-through.
Market effects
Reinforces demand for autoimmune diagnostics and revenue-cycle automation/appeals as a lever for ASP and collections in lab services.
No explicit regional market impact described.
Primarily US reimbursement and Medicare/LCD dynamics; limited global read-through.
Counterpoint
The guidance raise may be more about first-half outperformance and seasonality normalization than durable improvement, so second-half could still disappoint if LCD timing or volume from key clients shifts.
Key entities
- companyExagen Inc.
Reported record Q2 revenue, raised FY2026 revenue guidance, and outlined a path to adjusted EBITDA breakeven near $80M revenue.
- regulator/coverage bodyMolDX
Local Coverage Determination update timing is described as opaque and outside company control.
- product/test platformAVISE
Core test platform cited for record volumes and ASP growth drivers via new biomarkers.
